Biocept (BIOC) Stock

Biocept, Inc. (NASDAQ:BIOC ) Business Update Conference Call August 30, 2023 4:00 PM ET Company Participants Jody Cain - LHA Antonino Morales - President, CEO Dr. Barbara Blouw - VP, Clinical Development Dr. Seema Nagpal - Clinical Professor of Neurology-Stanford University Dr. Philippe Marchand - Chief Operating Officer Robert Walsh - Vice President, Controller Darrell Taylor - Chief Legal and Compliance Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Michael Okunewitch - Maxim Group Operator Welcome to the Biocept Business Update Conference Call. [Operator Instructions].

Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.

Biocept Inc (NASDAQ:BIOC) said that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 Society for Neuro-Oncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Cancer Conference which was held in San Fransico between August 10 and 12. The two abstracts presented were titled: “The HER2 Flip: HER2 Amplification of Tumor Cells in the Cerebrospinal Fluid (CSF-TCs) of Patients with Leptomeningeal Metastasis having solid tumors; implications for treating the LM tumor with anti-HER2 therapy,” and “Circulating tumor cell analysis from the cerebrospinal fluid informs early diagnosis, treatment and prognosis in leptomeningeal carcinomatosis (LMC).

Biocept Inc (NASDAQ:BIOC) has announced the appointment of Antonino Morales as its president and chief executive officer, effective immediately. Morales, who has been serving as the company's interim chief financial officer since February 2022 and as a director of the company since July 2021, will now take on the leadership role.

Biocept Inc (NASDAQ:BIOC) said that a poster presentation at the annual American Society of Clinical Oncology (ASCO) demonstrates the impressive ability of the company's cerebrospinal fluid assay CNSide to detect rates of leptomeningeal metastases, compared with standard CSF cytology from lumbar puncture. In a nutshell, leptomeningeal metastases (LM), is a type of cancer in the cerebrospinal fluid and membranes that surround a person's brain and spinal cord (the leptomeninges).

Biocept (NASDAQ: BIOC ) stock is falling hard on Thursday after the company revealed details of a public offering for its shares. Biocept is offering 1,176,470 shares of its common stock and warrants for up to 2,352,940 shares of BIOC stock.

Biocept has announced a one-for-thirty reverse stock split which became effective at 4:05pm Eastern Time on May 16, 2023. The company's common stock will begin trading on a split-adjusted basis as of the open of the market on May 17 under Biocept's existing ticker symbol “BIOC.

Biocept Inc (NASDAQ:BIOC), which develops and commercializes molecular diagnostic assays, revealed new details about its plans to get its CNSide assay system off the ground in 2023. Interim CEO Samuel Riccitelli told shareholders that the company decided that the best course of action is to further develop and commercialize CNSide while pursuing various options to extend its cash runway.